NRG Oncology May 29 2026 Previously, immature overall survival results of the NRG Oncology GY018 (NRG-GY018) trial suggested that the use of the immunotherapy drug pembrolizumab in combination with chemotherapy improved overall survival for patients with advanced stage or recurrent endometrial cancer when compared to chemotherapy alone. Notably, this benefit was observed in both the mismatch repair proficient (pMMR) and mismatch repair deficient (dMMR) populations. An analysis of the study data,